Great news to all patients. @GABOUALFA @sloan_kettering honored to have led and collaborated on the effort of @ExelixisInc Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma | Business Wire https://t.co/ncXVLHOM4z
This is the key chart that is on everyone’s mind today. $4.5B invested into US BioPharma by Chinese investors in 2018. How will it be impacted by the new CFIUS rule in 2019? Via Katherine Andersen of SVB. #JPM19
Putting kids who can’t consent at risk when CRISPR technology is still evolving is stupendously immoral. by @ArthurCaplan https://t.co/7xgFwAsBUZ #CRISPRbabies
Stephan A. Grupp, MD, PhD (@GruppSteve) will be speaking at Advanced Cell Therapy Shanghai Summit this October! View the full speaker list here: https://t.co/AMy7rO6LkP
Advanced Cell Therapy Shanghai Summit: 29– 31 Oct 2018 | Kerry Hotel Pudong, Shanghai #actss2018#phacilitate
Hear from a worldclass line-up of global regulatory experts and key opinion leaders on what it takes to successfully operate in #China https://t.co/vrC4mhxkWR
Advanced Cell Therapy Shanghai Summit: 29-31 October
#phacilitate@crconcology#actss2018#speakers#phacilitatevent